Cargando…
Comparison of 1-year therapeutic effect of ranibizumab and bevacizumab for myopic choroidal neovascularization: a retrospective, multicenter, comparative study
BACKGROUND: To compare the long-term efficacy of ranibizumab versus bevacizumab for myopic choroidal neovascularization (CNV). METHODS: This was a retrospective, multicenter, comparative, non-randomized study of 64 consecutive patients with myopic CNV treated with ranibizumab (22 patients) or bevaci...
Autores principales: | Cha, Dong Min, Kim, Tae Wan, Heo, Jang Won, Woo, Se Joon, Park, Kyu Hyung, Yu, Hyeong Gon, Chung, Hum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4042135/ https://www.ncbi.nlm.nih.gov/pubmed/24884970 http://dx.doi.org/10.1186/1471-2415-14-69 |
Ejemplares similares
-
Single intravitreal ranibizumab for myopic choroidal neovascularization
por: Nor-Masniwati, Saidin, et al.
Publicado: (2011) -
Treatment of myopic choroidal neovascularization with intravitreal ranibizumab injections: the role of age
por: Karagiannis, Dimitrios, et al.
Publicado: (2017) -
Intravitreal aflibercept versus bevacizumab for treatment of myopic choroidal neovascularization
por: Wang, Jia-Kang, et al.
Publicado: (2018) -
Results of Ranibizumab Treatment of the Myopic Choroidal Neovascular Membrane according to the Axial Length of the Eye
por: Stepanov, Alexandr, et al.
Publicado: (2020) -
Comparison of intravitreal bevacizumab and ranibizumab used for myopic choroidal neovascularization: A PRISMA-compliant systematic review and meta-analysis of randomized controlled trials
por: Hu, Qiuming, et al.
Publicado: (2019)